FGFR1 and non-small cell lung carcinoma: Thus, in the current study, we find that compound 15c, an EGFRL858R/T790M selective inhibitor in our previous study (Chen et al., 2017a), exhibited a dual inhibitory activity against EGFRL858R/T790M and FGFR1 and efficiently overcame the EGFR-TKI tolerance in EGFR-mutated NSCLC cells via concurrently inhibiting these two kinases activity.